Chimerix, Inc. (NASDAQ:CMRX) is reporting third quarter earnings results on Thursday 5th November 2020, before market open.
The consensus estimates from Thomson Reuters are loss of $ 0.17 per share.
For the full year, analysts predict revenues of $ 4.54 million, while looking forward to loss of $ 0.68 per share.
Previous Quarter Performance
Chimerix, Inc. unfold loss for the second quarter of $ 0.16 per share, from the revenue of $ 1.40 million. The quarterly revenues down 2.78 percent compared with the same quarter last year. The consensus estimates are loss of $ 0.17 per share from $ 1.06 million in revenue. The bottom line results beat street analysts by $ 0.01 or 5.88 percent, at the same time, top line results outshined analysts by $ 0.34 million or 32.08 percent.
Stock Performance
Shares of Chimerix, Inc. traded up $ 0.24 or 8.51 percent on Wednesday, reaching $ 3.06 with volume of 498.60 thousand shares. Chimerix, Inc. has traded high as $ 3.15 and has cracked $ 2.75 on the downward trend
The closing price of $ 3.06, representing a 136.97 % increase from the 52 week low of $ 1.19 and a 27.51 % decrease over the 52 week high of $ 3.89.
The company has a market capital of $ 201.62 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Chimerix, Inc. will be hosting a conference call at 8:30 AM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.chimerix.com
Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The companys lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients. It is also developing CMX521, a nucleoside for the treatment of norovirus; and CMX157, a nucleoside analog for the treatment of HIV and hepatitis B virus infection.
